The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.
Novo Nordisk's (NVO) weight loss therapy Wegovy/Ozempic come out of shortage, but the FDA won't crack down on compounders such as Him & Hers (HIMS). Read more here.
Novo Nordisk NVO has outperformed the market over the past 10 years by 3.2% on an annualized basis producing an average annual return of 14.24%. Currently, Novo Nordisk has a market capitalization of $392.
After quite a crushing bull stampede in 2024, the stock price of weight loss drug star Novo Nordisk ( NVO -1.54%) has come down considerably. But I think that not only will the Wegovy maker recover, it'll zoom much higher in the coming years.
In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of
Goldman Sachs analysts added Novo Nordisk (NVO) to the firm’s European Conviction List as part of its monthly update. Novo Nordisk’s recent